There is a reduced risk of cancer in patients suffering from certain forms of kidney disease, a new study has found.
Polycystic kidney disease (PKD) is a kidney disorder passed down through families in which many cysts form in the kidneys, causing them to become enlarged. It's thought to have cancer-like features, but cancer risk has never been compared between PKD patients and others with kidney disease. Cancer risk is also elevated in people who have received a kidney transplant, due to the immunosuppressive drugs they must take.
James B. Wetmore, MD, MS (University of Kansas Medical Center) and his colleagues conducted the first study to examine cancer risk in kidney transplant recipients with PKD and to compare their risk to that of other kidney transplant recipients.
After adjusting for demographic differences between kidney recipients with PKD and other recipients, PKD patients were 16% less likely to develop cancer than others who received a kidney transplant. Compared with the general population, overall cancer risk was increased 48% in PKD recipients, while the overall cancer risk in non-PKD recipients was increased 86%.
The findings indicate that PKD patients who received transplants do not have a higher risk of cancer than other kidney recipients. In fact, their cancer risk may be lower. "The reason for the decreased risk is uncertain, but some factor or factors in PKD patients-either inherent in the disease process itself or related to the care PKD patients receive-is associated with lower risks of cancers," said Dr. Wetmore. "Further study is required to determine how PKD might influence the development of cancer."
Dr. Wetmore speculated that PKD may induce certain anti-neoplastic defense mechanisms that guard against the subsequent development of cancer. Alternatively, it may be that PKD patients, who are frequently aware that they have a progressive medical condition and who therefore typically receive close medical care for many years or decades, engage in other healthy behaviors that prevent cancer.